Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)
China flag China · Delayed Price · Currency is CNY
9.63
+0.26 (2.78%)
Oct 23, 2026, 3:04 PM CST

SHE:000403 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
530.73770.161,3211,4291,001885.67
Trading Asset Securities
445.94254.39282.7423.34422.44234.21
Cash & Short-Term Investments
976.671,0251,6041,8531,4231,120
Cash Growth
-20.90%-36.12%-13.43%30.18%27.09%989.09%
Accounts Receivable
807.521,089710.69592.77891.08581.12
Other Receivables
5.639.176.542.3449.7112.83
Receivables
813.141,098717.19635.11940.79593.95
Inventory
1,9261,5781,245924.06623.69738.97
Prepaid Expenses
-18.9311.3712.350.140
Other Current Assets
52.411.241.611.8759.1216.53
Total Current Assets
3,7693,7213,5793,4263,0472,469
Property, Plant & Equipment
2,0572,0721,9991,5541,2971,103
Long-Term Investments
--6---
Goodwill
2,5362,5362,6152,6152,6152,615
Other Intangible Assets
176.72190.22200.33212.59192.52200.05
Long-Term Deferred Tax Assets
25.7826.5829.4349.0449.0927.35
Long-Term Deferred Charges
278.05229.9153.5579.4789.767.42
Other Long-Term Assets
822.2690.46664.24694.87692.81605.82
Total Assets
9,6659,4669,2468,6307,9827,088

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
238.94155.26224.26154.35158.37158.7
Accrued Expenses
23.32311.19335.48372.84373.49239.21
Short-Term Debt
581.34535.7310.49250.57275.1113.52
Current Portion of Long-Term Debt
58.7259.8417.0621.228.63-
Current Portion of Leases
-2.755.066.677.147.05
Current Income Taxes Payable
26.0315.5819.0739.7243.0824.22
Current Unearned Revenue
3.123.046.3610.7625.9111.54
Other Current Liabilities
354.0745.1239.266.0667.5888.04
Total Current Liabilities
1,2861,128956.97922.19959.31642.29
Long-Term Debt
344.87193.83303.22196.0852.89-
Long-Term Leases
12.8311.9418.621.4829.5920.89
Long-Term Unearned Revenue
55.9836.9726.8435.640.0849.24
Long-Term Deferred Tax Liabilities
11.5813.8714.1324.2630.3336.52
Other Long-Term Liabilities
--99911.14
Total Liabilities
1,7111,3851,3291,2091,121760.07

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
950.4950.4731.07733732.39732.92
Additional Paid-In Capital
4,5394,5394,758-4,7794,779
Retained Earnings
2,6082,5992,4351,9461,392846.23
Treasury Stock
-138.24---43.17-36.22-32
Comprehensive Income & Other
0.010.040.054,7930.04-0
Total Common Equity
7,9598,0887,9257,4296,8686,326
Minority Interest
-5.51-6.78-7.15-6.79-6.42.07
Shareholders' Equity
7,9548,0817,9187,4226,8616,328
Total Liabilities & Equity
9,6659,4669,2468,6307,9827,088

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
997.77804.06654.44496.02373.36141.46
Net Cash (Debt)
-21.1220.48949.391,3571,050978.42
Net Cash Growth
--76.78%-30.02%29.22%7.30%-
Net Cash Per Share
-0.020.230.991.431.101.06
Filing Date Shares Outstanding
937.54950.4950.4950.06952.1952.8
Total Common Shares Outstanding
937.54950.4950.4950.34952.1952.8
Working Capital
2,4832,5932,6222,5042,0881,827
Book Value Per Share
8.498.518.347.827.216.64
Tangible Book Value
5,2475,3625,1104,6014,0603,511
Tangible Book Value Per Share
5.605.645.384.844.263.68
Buildings
-1,2661,180833.6701.14583.25
Machinery
-1,5631,184961.1920.37729.45
Construction In Progress
-225.99513.36582.7385.73334.38